clinical trial · NCT01297400
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
Skingenix, Inc.·phase2·recruiting·n = 60
BurnsInvestigational Drug, MW-IIISilvadene® Cream 1% [Silver Sulfadiazine]
brief summary
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
started
Mar 11, 2022
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Mar 16, 2026
detailed description
This phase 2 pilot study will assess the safety and efficacy of topical MW-III on thermal burns.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol